Previous reports on clinical characteristics, outcome, and prognostic factors of patients with MCL
| First author . | Tiemann . | Räty . | Samaha . | Andersen . | Schrader . | Oinonen . | Møller . | Argatoff . | Weisenburger . | Zucca . | Bosch . | Decaudin . | Velders . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | 17 | 15 | 13 | 1 | 16 | 12 | 20 | 4 | 14 | 9 | 11 | 10 | 2 |
| Number | 304 | 127 | 121 | 105* | 95 | 94 | 93* | 80* | 68 | 65 | 59 | 45 | 41* |
| Median age, y | 64 | 65 | 63 | 66 | 62% (> 60) | 66 | 68 | 65 | 64 | 64 | 63 | 59 | 68 |
| Male, % | 76 | 64 | 67 | 75 | 77 | 59 | 71 | 70 | 75 | 67 | 74 | 78 | 61 |
| Stage I/II, % | 8 | 17 | 13 | 16 | 8 | 24 | 17 | 14 | 25 | 22 | 5 | 13 | 20 |
| Median OS, mo | ∼36 | 34 | 37 | 30 | ∼30 | 41 | 37 | 43 | 38 | 42 | 49 | ∼56 | 31.5 |
| Older than 60 y | + | na | +† | +‡ | + | + | na | − | na | +‡ | − | na | na |
| Sex | − | na | na | − | − | − | na | na | na | − | − | na | na |
| ECOG 2-4 vs 0-1 | + | na | + | + | − | +§ | + | + | + | − | + | na | + |
| Stage III/IV vs I/II | + | na | + | + | − | + | na | − | −‖ | − | −¶ | − | + |
| B-symptoms | + | na | – | − | − | + | na | na | + | − | + | na | na |
| Spleen inv. | na | na | + | + | na | − | na | na | na | − | + | – | na |
| Bone marrow inv. | + | na | na | − | − | + | na | na | + | − | na | + | + |
| Peripheral blood inv. | na | na | + | na | na | + | na | + | na | na | − | −‖ | na |
| Extranodal sites, more than 1 | +| | na | + | − | −| | − | − | − | na | na | − | − | + |
| Bulk, larger than 10 cm | na | na | − | na | na | − | na | na | na | na | na | na | na |
| Elevated LDH | + | na | + | + | + | + | na | − | na | + | + | − | − |
| WBC count | na | na | na | + | na | + | na | na | na | na | + | na | na |
| Hemoglobin | na | na | + | + | na | + | + | na | na | na | na | − | na |
| Growth pattern | + | + | − | na | na | na | na | − | + | na | na | na | na |
| Cytology | − | + | − | na | na | na | na | + | + | na | + | −‖ | na |
| Mitotic index | + | + | na | na | na | na | na | + | − | na | + | na | na |
| Ki-67 | + | + | na | − | + | na | na | na | na | na | na | na | + |
| IPI | − | na | +** | + | + | +†† | +‡‡ | − | + | +†† | + | − | +‡‡ |
| IPI risk group, no. | 2 | na | 4 | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 2 | 2 | 4 |
| First author . | Tiemann . | Räty . | Samaha . | Andersen . | Schrader . | Oinonen . | Møller . | Argatoff . | Weisenburger . | Zucca . | Bosch . | Decaudin . | Velders . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | 17 | 15 | 13 | 1 | 16 | 12 | 20 | 4 | 14 | 9 | 11 | 10 | 2 |
| Number | 304 | 127 | 121 | 105* | 95 | 94 | 93* | 80* | 68 | 65 | 59 | 45 | 41* |
| Median age, y | 64 | 65 | 63 | 66 | 62% (> 60) | 66 | 68 | 65 | 64 | 64 | 63 | 59 | 68 |
| Male, % | 76 | 64 | 67 | 75 | 77 | 59 | 71 | 70 | 75 | 67 | 74 | 78 | 61 |
| Stage I/II, % | 8 | 17 | 13 | 16 | 8 | 24 | 17 | 14 | 25 | 22 | 5 | 13 | 20 |
| Median OS, mo | ∼36 | 34 | 37 | 30 | ∼30 | 41 | 37 | 43 | 38 | 42 | 49 | ∼56 | 31.5 |
| Older than 60 y | + | na | +† | +‡ | + | + | na | − | na | +‡ | − | na | na |
| Sex | − | na | na | − | − | − | na | na | na | − | − | na | na |
| ECOG 2-4 vs 0-1 | + | na | + | + | − | +§ | + | + | + | − | + | na | + |
| Stage III/IV vs I/II | + | na | + | + | − | + | na | − | −‖ | − | −¶ | − | + |
| B-symptoms | + | na | – | − | − | + | na | na | + | − | + | na | na |
| Spleen inv. | na | na | + | + | na | − | na | na | na | − | + | – | na |
| Bone marrow inv. | + | na | na | − | − | + | na | na | + | − | na | + | + |
| Peripheral blood inv. | na | na | + | na | na | + | na | + | na | na | − | −‖ | na |
| Extranodal sites, more than 1 | +| | na | + | − | −| | − | − | − | na | na | − | − | + |
| Bulk, larger than 10 cm | na | na | − | na | na | − | na | na | na | na | na | na | na |
| Elevated LDH | + | na | + | + | + | + | na | − | na | + | + | − | − |
| WBC count | na | na | na | + | na | + | na | na | na | na | + | na | na |
| Hemoglobin | na | na | + | + | na | + | + | na | na | na | na | − | na |
| Growth pattern | + | + | − | na | na | na | na | − | + | na | na | na | na |
| Cytology | − | + | − | na | na | na | na | + | + | na | + | −‖ | na |
| Mitotic index | + | + | na | na | na | na | na | + | − | na | + | na | na |
| Ki-67 | + | + | na | − | + | na | na | na | na | na | na | na | + |
| IPI | − | na | +** | + | + | +†† | +‡‡ | − | + | +†† | + | − | +‡‡ |
| IPI risk group, no. | 2 | na | 4 | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 2 | 2 | 4 |
Prognostic relevance reported from univariate analyses on significance level .05 for overall survival.
+ indicates prognostic; −, not prognostic; inv, involvement; and na, not analyzed.
Population based data.
Age cutpoint 70 years.
Age cutpoint 65 years.
ECOG performance status 0 vs > 0.
Stage I-III vs. IV.
P < .1.
LR, LIR, HIR not separated.
LIR, HIR not separated.
LIR, HIR, HR not separated.
Extra nodal involvement, yes vs no.